These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Design, synthesis and evaluation of covalent inhibitors of DprE1 as antitubercular agents. Liu L; Kong C; Fumagalli M; Savková K; Xu Y; Huszár S; Sammartino JC; Fan D; Chiarelli LR; Mikušová K; Sun Z; Qiao C Eur J Med Chem; 2020 Dec; 208():112773. PubMed ID: 32898793 [TBL] [Abstract][Full Text] [Related]
4. Biological and structural characterization of the Mycobacterium smegmatis nitroreductase NfnB, and its role in benzothiazinone resistance. Manina G; Bellinzoni M; Pasca MR; Neres J; Milano A; Ribeiro AL; Buroni S; Skovierová H; Dianišková P; Mikušová K; Marák J; Makarov V; Giganti D; Haouz A; Lucarelli AP; Degiacomi G; Piazza A; Chiarelli LR; De Rossi E; Salina E; Cole ST; Alzari PM; Riccardi G Mol Microbiol; 2010 Sep; 77(5):1172-85. PubMed ID: 20624223 [TBL] [Abstract][Full Text] [Related]
5. Towards a new combination therapy for tuberculosis with next generation benzothiazinones. Makarov V; Lechartier B; Zhang M; Neres J; van der Sar AM; Raadsen SA; Hartkoorn RC; Ryabova OB; Vocat A; Decosterd LA; Widmer N; Buclin T; Bitter W; Andries K; Pojer F; Dyson PJ; Cole ST EMBO Mol Med; 2014 Mar; 6(3):372-83. PubMed ID: 24500695 [TBL] [Abstract][Full Text] [Related]
6. Structure, dynamics, and interaction of Mycobacterium tuberculosis (Mtb) DprE1 and DprE2 examined by molecular modeling, simulation, and electrostatic studies. Bhutani I; Loharch S; Gupta P; Madathil R; Parkesh R PLoS One; 2015; 10(3):e0119771. PubMed ID: 25789990 [TBL] [Abstract][Full Text] [Related]
7. DprE1--from the discovery to the promising tuberculosis drug target. Mikusová K; Makarov V; Neres J Curr Pharm Des; 2014; 20(27):4379-403. PubMed ID: 24245764 [TBL] [Abstract][Full Text] [Related]
8. Crystal structure of decaprenylphosphoryl-β- D-ribose 2'-epimerase from Mycobacterium smegmatis. Li H; Jogl G Proteins; 2013 Mar; 81(3):538-43. PubMed ID: 23184707 [TBL] [Abstract][Full Text] [Related]
9. In vitro combination studies of benzothiazinone lead compound BTZ043 against Mycobacterium tuberculosis. Lechartier B; Hartkoorn RC; Cole ST Antimicrob Agents Chemother; 2012 Nov; 56(11):5790-3. PubMed ID: 22926573 [TBL] [Abstract][Full Text] [Related]
10. The 8-Pyrrole-Benzothiazinones Are Noncovalent Inhibitors of DprE1 from Mycobacterium tuberculosis. Makarov V; Neres J; Hartkoorn RC; Ryabova OB; Kazakova E; Šarkan M; Huszár S; Piton J; Kolly GS; Vocat A; Conroy TM; Mikušová K; Cole ST Antimicrob Agents Chemother; 2015 Aug; 59(8):4446-52. PubMed ID: 25987616 [TBL] [Abstract][Full Text] [Related]
11. Fluorescent Benzothiazinone Analogues Efficiently and Selectively Label Dpre1 in Mycobacteria and Actinobacteria. Sommer R; Neres J; Piton J; Dhar N; van der Sar A; Mukherjee R; Laroche T; Dyson PJ; McKinney JD; Bitter W; Makarov V; Cole ST ACS Chem Biol; 2018 Nov; 13(11):3184-3192. PubMed ID: 30289689 [TBL] [Abstract][Full Text] [Related]
12. Clinical isolates of Mycobacterium tuberculosis in four European hospitals are uniformly susceptible to benzothiazinones. Pasca MR; Degiacomi G; Ribeiro AL; Zara F; De Mori P; Heym B; Mirrione M; Brerra R; Pagani L; Pucillo L; Troupioti P; Makarov V; Cole ST; Riccardi G Antimicrob Agents Chemother; 2010 Apr; 54(4):1616-8. PubMed ID: 20086151 [TBL] [Abstract][Full Text] [Related]
13. 2-Carboxyquinoxalines kill mycobacterium tuberculosis through noncovalent inhibition of DprE1. Neres J; Hartkoorn RC; Chiarelli LR; Gadupudi R; Pasca MR; Mori G; Venturelli A; Savina S; Makarov V; Kolly GS; Molteni E; Binda C; Dhar N; Ferrari S; Brodin P; Delorme V; Landry V; de Jesus Lopes Ribeiro AL; Farina D; Saxena P; Pojer F; Carta A; Luciani R; Porta A; Zanoni G; De Rossi E; Costi MP; Riccardi G; Cole ST ACS Chem Biol; 2015 Mar; 10(3):705-14. PubMed ID: 25427196 [TBL] [Abstract][Full Text] [Related]
19. Novel insight into the reaction of nitro, nitroso and hydroxylamino benzothiazinones and of benzoxacinones with Mycobacterium tuberculosis DprE1. Richter A; Rudolph I; Möllmann U; Voigt K; Chung CW; Singh OMP; Rees M; Mendoza-Losana A; Bates R; Ballell L; Batt S; Veerapen N; Fütterer K; Besra G; Imming P; Argyrou A Sci Rep; 2018 Sep; 8(1):13473. PubMed ID: 30194385 [TBL] [Abstract][Full Text] [Related]
20. Bridging the gap between a TB drug and its target. Cook GM; Heikal A Sci Transl Med; 2012 Sep; 4(150):150fs33. PubMed ID: 22956196 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]